JP2017519039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519039A5 JP2017519039A5 JP2017511547A JP2017511547A JP2017519039A5 JP 2017519039 A5 JP2017519039 A5 JP 2017519039A5 JP 2017511547 A JP2017511547 A JP 2017511547A JP 2017511547 A JP2017511547 A JP 2017511547A JP 2017519039 A5 JP2017519039 A5 JP 2017519039A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- collix
- toxin
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 241001269314 Collix Species 0.000 claims 14
- 239000003053 toxin Substances 0.000 claims 14
- 231100000765 toxin Toxicity 0.000 claims 14
- 230000004927 fusion Effects 0.000 claims 13
- 230000000975 bioactive effect Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims 2
- 239000000854 Human Growth Hormone Substances 0.000 claims 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 2
- 102000001974 Hyaluronidases Human genes 0.000 claims 2
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 229960002773 hyaluronidase Drugs 0.000 claims 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960005202 streptokinase Drugs 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 1
- 102100036717 Growth hormone variant Human genes 0.000 claims 1
- 101710191157 Growth hormone variant Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102100039879 Interleukin-19 Human genes 0.000 claims 1
- 108050009288 Interleukin-19 Proteins 0.000 claims 1
- 102100030692 Interleukin-20 Human genes 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102100036671 Interleukin-24 Human genes 0.000 claims 1
- 102100036679 Interleukin-26 Human genes 0.000 claims 1
- 101710181612 Interleukin-26 Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 claims 1
- 101710142969 Somatoliberin Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108090000681 interleukin 20 Proteins 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 108010074109 interleukin-22 Proteins 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990054P | 2014-05-07 | 2014-05-07 | |
| US61/990,054 | 2014-05-07 | ||
| PCT/US2015/029795 WO2015171965A2 (en) | 2014-05-07 | 2015-05-07 | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020147344A Division JP7125453B2 (ja) | 2014-05-07 | 2020-09-02 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519039A JP2017519039A (ja) | 2017-07-13 |
| JP2017519039A5 true JP2017519039A5 (enExample) | 2018-06-14 |
| JP6759188B2 JP6759188B2 (ja) | 2020-09-23 |
Family
ID=54393149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511547A Active JP6759188B2 (ja) | 2014-05-07 | 2015-05-07 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
| JP2020147344A Active JP7125453B2 (ja) | 2014-05-07 | 2020-09-02 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020147344A Active JP7125453B2 (ja) | 2014-05-07 | 2020-09-02 | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Country Status (19)
| Country | Link |
|---|---|
| US (9) | US10624955B2 (enExample) |
| EP (2) | EP3139965B1 (enExample) |
| JP (2) | JP6759188B2 (enExample) |
| KR (2) | KR102598038B1 (enExample) |
| CN (2) | CN106470707A (enExample) |
| AU (2) | AU2015255834B2 (enExample) |
| BR (1) | BR112016025866A2 (enExample) |
| CA (1) | CA2948346C (enExample) |
| DK (1) | DK3139965T3 (enExample) |
| ES (1) | ES2900328T3 (enExample) |
| IL (2) | IL285716B (enExample) |
| MX (2) | MX385898B (enExample) |
| PH (2) | PH12016502447B1 (enExample) |
| PL (1) | PL3139965T3 (enExample) |
| PT (1) | PT3139965T (enExample) |
| RU (1) | RU2723178C2 (enExample) |
| SG (1) | SG11201610183XA (enExample) |
| SI (1) | SI3139965T1 (enExample) |
| WO (1) | WO2015171965A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| DK3139965T3 (da) * | 2014-05-07 | 2021-11-22 | Applied Molecular Transport Inc | Fusionsmolekyler afledt af cholix-toksin til oral indgivelse af biologisk aktive stoffer |
| US10676723B2 (en) * | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2018075357A1 (en) | 2016-10-17 | 2018-04-26 | Duke University | PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL |
| AU2019230230B2 (en) * | 2018-03-08 | 2025-04-10 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| EP4082558B1 (en) | 2018-03-08 | 2023-08-23 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| SG11202104734YA (en) * | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Cholix-derived carriers for oral delivery of heterologous payload |
| KR20210110294A (ko) * | 2018-11-07 | 2021-09-07 | 어플라이드 몰레큘라 트랜스포트 인크. | 통과세포외배출용 전달 구조체 및 관련 방법 |
| WO2020237322A1 (en) * | 2019-05-31 | 2020-12-03 | Lateral IP Pty Ltd | Peptides and uses thereof |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
| CN114555058A (zh) * | 2019-08-16 | 2022-05-27 | 应用分子转运公司 | 用于有效载荷递送的组合物和颗粒 |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| IT202000028418A1 (it) * | 2020-11-25 | 2022-05-25 | Raicam Driveline S R L | Unità valvolare per un sistema di frenatura antibloccaggio |
| WO2023196532A1 (en) * | 2022-04-08 | 2023-10-12 | Applied Molecular Transport Inc. | Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1014372A (en) | 1910-12-01 | 1912-01-09 | Bush Mfg Company | Hinge. |
| US1013068A (en) | 1911-09-09 | 1911-12-26 | Frederick F Mcintosh | Single-trigger gun mechanism. |
| US2643653A (en) | 1951-07-19 | 1953-06-30 | Heidrich John | Pill injector |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0092227B1 (en) | 1982-04-19 | 1988-07-27 | Nissan Motor Co., Ltd. | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US5272065A (en) | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US6051405A (en) | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US5807832A (en) | 1987-06-09 | 1998-09-15 | Biotech Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin B12 |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| EP0531434B1 (en) | 1990-05-11 | 1999-07-14 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity |
| GB9112553D0 (en) | 1991-06-11 | 1991-07-31 | Wellcome Found | Fusion proteins |
| CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
| US5487994A (en) * | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| JP3553933B2 (ja) | 1992-06-18 | 2004-08-11 | アメリカ合衆国 | 高められた活性を有する組換シュードモナス外毒素 |
| WO1994017819A1 (en) | 1993-02-02 | 1994-08-18 | Xoma Corporation | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
| GB9401787D0 (en) | 1994-01-31 | 1994-03-23 | Medeva Holdings Bv | Vaccine compositions |
| GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
| GB9420355D0 (en) | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| DE69838667T2 (de) | 1997-08-01 | 2008-10-30 | Toray Industries, Inc. | Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel |
| US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| US7053200B1 (en) | 1999-06-01 | 2006-05-30 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation |
| CN1245216C (zh) | 1999-10-04 | 2006-03-15 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| ES2332261T3 (es) | 2000-11-27 | 2010-02-01 | Powderject Vaccines, Inc. | Adyuvantes de acidos nucleicos. |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
| AU2002339121B2 (en) | 2001-05-23 | 2007-03-22 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| JP4623625B2 (ja) | 2003-07-24 | 2011-02-02 | 株式会社AMBiS | ヘテロ型５量体組換えワクチン |
| EP1522585A1 (en) | 2003-10-09 | 2005-04-13 | Plant Research International B.V. | Chimeric carrier molecules for the production of mucosal vaccines |
| AU2004299501B2 (en) * | 2003-12-17 | 2010-12-23 | Wyeth Llc | Immunogenic peptide carrier conjugates and methods of producing same |
| US20080317761A1 (en) | 2004-04-28 | 2008-12-25 | The Trustees Of The University Of Pennsylvania | Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage |
| US20050281885A1 (en) * | 2004-06-21 | 2005-12-22 | Egilmez Nejat K | Method for treating inflammatory bowel disease by oral administration of IL-10 |
| US20090155297A1 (en) | 2004-10-04 | 2009-06-18 | Trinity Biosystems, Inc. | Methods and Compositions for Inducing an Immune Response Against Multiple Antigens |
| EP1804832A4 (en) | 2004-10-04 | 2008-12-24 | Trinity Biosystems Inc | METHOD AND COMPOSITIONS FOR THE NADLESS DELIVERY OF MACROMOLECULES |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| PL3006458T3 (pl) | 2005-07-29 | 2018-05-30 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości |
| US20090148401A1 (en) | 2005-12-05 | 2009-06-11 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| CA2647168A1 (en) | 2006-03-16 | 2007-09-27 | Trinity Biosystems, Inc. | Methods for increasing the size of animals using needleless delivery constructs |
| WO2008011157A2 (en) | 2006-07-20 | 2008-01-24 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
| US20100196277A1 (en) | 2006-10-09 | 2010-08-05 | The University Of North Carolina At Chapel Hill | Nanoparticle compositions for controlled delivery of nucleic acids |
| WO2008147526A1 (en) | 2007-05-23 | 2008-12-04 | The Trustees Of The University Of Pennsylvania | Targeted carriers for intracellular drug delivery |
| JP2010534061A (ja) | 2007-07-20 | 2010-11-04 | ザ ジェネラル ホスピタル コーポレイション | 組換えコレラ菌外毒素 |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| WO2009026328A2 (en) | 2007-08-21 | 2009-02-26 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
| JP5670875B2 (ja) | 2008-03-17 | 2015-02-18 | ウニベルジテーツクリニクム ミュンスター | カーゴ分子の送達ビヒクルおよび炎症反応を免疫調節するための生物学的治療剤としてのＹｏｐＭ |
| US20110250199A1 (en) * | 2008-06-04 | 2011-10-13 | The Government of the United States of America as represented by the Secretary of the Department.... | Immunotoxins and uses thereof |
| CN107056951A (zh) | 2008-10-02 | 2017-08-18 | 阿帕特夫研究和发展有限公司 | Cd86拮抗物多靶点结合蛋白 |
| EP2456470A1 (en) | 2009-07-22 | 2012-05-30 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) * | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| JP2014505064A (ja) * | 2011-01-26 | 2014-02-27 | セニックス バイオサイエンス ゲーエムベーハー | 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート |
| WO2012110596A1 (en) * | 2011-02-16 | 2012-08-23 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fusion protein for the treatment of immunologic or allergic reactions |
| CN104023740B (zh) * | 2011-06-29 | 2018-10-02 | 拉尼医疗有限公司 | 用于使用可吞服药物递送装置递送到肠道内腔中的治疗药剂制剂 |
| HK1215595A1 (zh) | 2013-04-24 | 2016-09-02 | Armo Biosciences, Inc. | 白細胞介素-10藥物組合物和使用方法 |
| AU2014346554B2 (en) | 2013-11-07 | 2020-06-04 | Evive Biotechnology (Shanghai) Ltd | Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| KR102500408B1 (ko) | 2014-01-27 | 2023-02-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
| DK3139965T3 (da) | 2014-05-07 | 2021-11-22 | Applied Molecular Transport Inc | Fusionsmolekyler afledt af cholix-toksin til oral indgivelse af biologisk aktive stoffer |
| CA2963995A1 (en) | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017118985A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| US11110122B2 (en) | 2016-06-03 | 2021-09-07 | New York University | Methods and reagents for modulating macrophage phenotype |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| WO2018112255A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CA3054156A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
| AU2019230230B2 (en) | 2018-03-08 | 2025-04-10 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| SG11202104734YA (en) | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Cholix-derived carriers for oral delivery of heterologous payload |
-
2015
- 2015-05-07 DK DK15788688.8T patent/DK3139965T3/da active
- 2015-05-07 CN CN201580036678.8A patent/CN106470707A/zh active Pending
- 2015-05-07 WO PCT/US2015/029795 patent/WO2015171965A2/en not_active Ceased
- 2015-05-07 CA CA2948346A patent/CA2948346C/en active Active
- 2015-05-07 JP JP2017511547A patent/JP6759188B2/ja active Active
- 2015-05-07 PL PL15788688T patent/PL3139965T3/pl unknown
- 2015-05-07 US US15/309,177 patent/US10624955B2/en active Active
- 2015-05-07 SG SG11201610183XA patent/SG11201610183XA/en unknown
- 2015-05-07 EP EP15788688.8A patent/EP3139965B1/en active Active
- 2015-05-07 CN CN202311263281.5A patent/CN117298254A/zh active Pending
- 2015-05-07 KR KR1020167034104A patent/KR102598038B1/ko active Active
- 2015-05-07 IL IL285716A patent/IL285716B/en unknown
- 2015-05-07 SI SI201531758T patent/SI3139965T1/sl unknown
- 2015-05-07 PT PT157886888T patent/PT3139965T/pt unknown
- 2015-05-07 EP EP21199457.9A patent/EP3998077A1/en active Pending
- 2015-05-07 KR KR1020237037526A patent/KR20230154480A/ko not_active Ceased
- 2015-05-07 AU AU2015255834A patent/AU2015255834B2/en active Active
- 2015-05-07 MX MX2016014548A patent/MX385898B/es unknown
- 2015-05-07 ES ES15788688T patent/ES2900328T3/es active Active
- 2015-05-07 BR BR112016025866A patent/BR112016025866A2/pt not_active Application Discontinuation
- 2015-05-07 RU RU2016147734A patent/RU2723178C2/ru active
-
2016
- 2016-11-06 IL IL248768A patent/IL248768B/en unknown
- 2016-11-07 MX MX2021010666A patent/MX2021010666A/es unknown
- 2016-12-12 PH PH12016502447A patent/PH12016502447B1/en unknown
-
2017
- 2017-06-07 US US15/616,140 patent/US10130688B2/en active Active
-
2018
- 2018-10-04 US US16/151,533 patent/US10799565B2/en active Active
- 2018-12-03 US US16/207,611 patent/US10624956B2/en active Active
- 2018-12-03 US US16/207,637 patent/US10624957B2/en active Active
- 2018-12-03 US US16/207,655 patent/US10786555B2/en active Active
- 2018-12-14 US US16/220,923 patent/US10786556B2/en active Active
-
2020
- 2020-07-20 AU AU2020207779A patent/AU2020207779A1/en not_active Abandoned
- 2020-08-19 US US16/997,781 patent/US20210205420A1/en not_active Abandoned
- 2020-09-02 JP JP2020147344A patent/JP7125453B2/ja active Active
-
2021
- 2021-05-24 PH PH12021551189A patent/PH12021551189A1/en unknown
-
2023
- 2023-04-06 US US18/131,560 patent/US20240226243A9/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519039A5 (enExample) | ||
| US9358308B2 (en) | Compositions of a peptide targeting system for treating cancer | |
| Nowakowski et al. | Engineered mesenchymal stem cells as an anti-cancer trojan horse | |
| JP2019524721A (ja) | キメラ抗原受容体および使用方法 | |
| KR102741572B1 (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| KR20200123139A (ko) | 코딩 리보핵산의 기관 보호적 발현 및 조절을 위한 조성물 및 방법 | |
| JP2019528044A (ja) | Ｍｕｃ１に特異的なキメラ抗原受容体（ｃａｒｓ）およびその使用方法 | |
| JP2020521445A5 (enExample) | ||
| MXPA06004199A (es) | Terapia en combinacion. | |
| US20220062383A1 (en) | Regulation of a foreign body response | |
| CN113039194A (zh) | 具有免疫调节特性的肽 | |
| US20180117176A1 (en) | Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity | |
| RU2803294C2 (ru) | Композиции и способы органно-защитной экспрессии и модуляции кодирующих рибонуклеиновых кислот | |
| Wang et al. | A Combinatorial mRNA Therapy for Treating Rheumatoid Arthritis and Osteoarthritis by Inhibiting Inflammation and Promoting Cartilage Regeneration | |
| ES2373151A1 (es) | Uso de inhibidores de edg2 para el tratamiento de la artritis reumatoide. | |
| Yoon et al. | 116. Overcoming CAR-Dependency of Oncolytic Adenovirus via Adenoviral Fiber Modification with Vesicular Stomatitis Virus Glycoprotein Epitope for Enhanced Antitumor Efficacy | |
| Han et al. | 270. Nanoparticle-Mediated Rhodopsin cDNA But Not the Intron-Containing DNA Delivery Causes Transgene Silencing in a Rhodopsin Knockout Model | |
| HK40022397B (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
| HK40022397A (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue |